The antidepressant sertraline downregulates Akt and has activity against melanoma cells

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Melanoma exhibits poor response to conventional therapies like chemotherapy and radiation.
• Constitutive activation of Akt signaling confers resistance to apoptosis in melanoma cells.

Purpose of the Study:

• To investigate the cytotoxic effects and underlying mechanisms of sertraline in human melanoma cells.
• To evaluate the in vivo efficacy of sertraline against melanoma xenografts.

Main Methods:

• Western blot analysis to assess signaling molecules (e.g., phosphorylated Akt, caspase 9).
• In vitro cytotoxicity assays against A375 human melanoma cells.
• In vivo studies using A375 xenografts in mice.

Main Results:

• Sertraline demonstrated potent inhibition of Akt phosphorylation in melanoma cells.
• Sertraline induced cell death via endoplasmic reticulum stress.
• Sertraline monotherapy showed significant activity against A375 xenografts in vivo.

Conclusions:

• Sertraline exhibits potent anti-melanoma activity, targeting Akt signaling and inducing apoptosis.
• Sertraline represents a potential therapeutic agent for melanoma, possibly enhancing current treatments.
• Further research is warranted to confirm sertraline's role as an Akt inhibitor in melanoma.